There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aerie Pharma (AERI), Dynavax (DVAX) and Heat Biologics (HTBX) with bullish sentiments.
Aerie Pharma (AERI)
Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on Aerie Pharma yesterday and set a price target of $105. The company’s shares closed yesterday at $46.13.
According to TipRanks.com, Cacciatore is a 1-star analyst with an average return of -1.5% and a 43.8% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Supernus Pharmaceuticals, and Alder Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $76.67 average price target, a 66.2% upside from current levels. In a report issued on February 12, Canaccord Genuity also reiterated a Buy rating on the stock with a $86 price target.
See today’s analyst top recommended stocks >>
Dynavax (DVAX)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Dynavax yesterday and set a price target of $30. The company’s shares closed yesterday at $10.56.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.0% and a 48.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Dynavax is a Moderate Buy with an average price target of $28, a 165.2% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.
Heat Biologics (HTBX)
In a report released yesterday, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on Heat Biologics, with a price target of $8. The company’s shares closed yesterday at $1.58.
Raja commented:
“An abstract for HS-110 combo with checkpoint inhibitor nivolumab was released. The interim data indicated that HS-110 combo with nivolumab leads to meaningful benefit consistent with earlier results. We expect that the presentation at 2019 will contain updated results with a later cut-off date.”
According to TipRanks.com, Raja is a 1-star analyst with an average return of -4.3% and a 46.9% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Acer Therapeutics Inc, and Rexahn Pharma.
Currently, the analyst consensus on Heat Biologics is a Moderate Buy with an average price target of $8.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
